Micrograph News and Research

RSS

Alarming spread of H5N1 bird flu in US dairy cattle reveals cross-species transmission dangers

Researchers discovered that the H5N1 avian influenza virus has spilled over into dairy cattle in the US, posing significant cross-species transmission risks. Their multidisciplinary study reveals the virus's evolution and its zoonotic potential, emphasizing the need for heightened biosecurity measures.

25 Jul 2024

Reliability of HIV viral load tests for CAB-LA PrEP questioned in new study

A single laboratory-based HIV viral load test used by U.S. clinicians who provide people with long-acting, injectable cabotegravir (CAB-LA) HIV pre-exposure prophylaxis (PrEP) did not reliably detect HIV in a multi-country study.

23 Jul 2024

Abacavir linked to increased cardiovascular risk in HIV patients, study finds

CJ Fichtenbaum et al. Abacavir is associated with elevated risk for cardiovascular events in the REPRIEVE trial. International AIDS Conference. Friday, July 26, 2024

23 Jul 2024

Long-acting injectable CAB-LA safe for HIV PrEP during pregnancy, study finds

Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy in the follow-up phase of a global study among cisgender women.

23 Jul 2024

Rise of multidrug-resistant Salmonella strains in U.S. retail chicken meat

Salmonella infections are a major public health issue in the United States, causing over 1.3 million illnesses annually.

18 Jul 2024

NIH launches Phase 1 trial for innovative nasal COVID-19 vaccine

A Phase 1 trial testing the safety of an experimental nasal vaccine that may provide enhanced breadth of protection against emerging variants of SARS-CoV-2, the virus that causes COVID-19, is now enrolling healthy adults at three sites in the United States.

1 Jul 2024

Clinical trial seeks to evaluate safety of new EV-D68 treatment

The National Institutes of Health (NIH) is sponsoring a clinical trial to evaluate the safety of an investigational monoclonal antibody to treat enterovirus D68 (EV-D68), which can cause severe respiratory and neurological diseases such as acute flaccid myelitis (AFM) – similar to polio. Scientists are striving to better understand AFM, which has emerged in the United States with spikes in cases every other year, primarily in the late-summer months over the last decade.

28 Jun 2024

NIAID scientists discover probiotic treatment for eczema

NIAID research has led to the availability of a new over-the-counter topical eczema probiotic.

26 Jun 2024

Novel approach can make many more bacteria amenable to genetic engineering

Bacteria possess unique traits with great potential for benefiting society. However, current genetic engineering methods to harness these advantages are limited to a small fraction of bacterial species.

26 Jun 2024

Lenacapavir: A breakthrough in long-acting HIV prevention for cisgender women

The injectable antiretroviral drug lenacapavir was safe and 100% effective as long-acting HIV pre-exposure prophylaxis (PrEP) among cisgender women in a Phase 3 clinical trial, according to top-line findings released by Gilead Sciences, Inc., the study sponsor.

26 Jun 2024

Novel CMOS sensor captures fast and subtle neural voltage fluctuations

Neurons communicate electrically so to understand how they produce brain functions such as memory, neuroscientists must track how their voltage changes-;sometimes subtly-;on the timescale of milliseconds.

7 Jun 2024

Understanding the role of tumor-associated fibrosis in immunotherapy resistance

Immunotherapy is based on harnessing a person's own immune system to attack cancer cells.

4 Jun 2024

Engineered immunogens show promise in inducing HIV broadly neutralizing antibodies

Using a combination of cutting-edge immunologic technologies, researchers have successfully stimulated animals' immune systems to induce rare precursor B cells of a class of HIV broadly neutralizing antibodies (bNAbs).

30 May 2024

Study identifies key gluten peptide triggering leaky gut in celiac patients

Today is International Celiac Day. Celiac disease is a chronic autoimmune condition that occurs in around one per cent of the world's population.

17 May 2024

Drug repurposing breakthrough: varespladib curbs snakebite-induced necrosis

Researchers discovered that venom toxins from African spitting cobras cause severe dermonecrosis, highlighting the need for targeted treatments like the repurposed drug varespladib.

9 May 2024

First-of-its-kind AI tool predicts patient response to cancer drugs at single-cell resolution

With more than 200 types of cancer and every cancer individually unique, ongoing efforts to develop precision oncology treatments remain daunting.

18 Apr 2024

Restoring insulin sensitivity without TZD side effects

Thiazolidinediones (TZDs) are a class of drug that can be used to treat type 2 diabetes by reversing insulin resistance, one of the main hallmarks of the disease.

13 Apr 2024

NIH study uncovers vulnerable sites on Epstein-Barr virus protein

Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for this extremely common virus.

12 Mar 2024

Vaginal ring and oral PrEP found to be safe for HIV prevention among pregnant cisgender women

The monthly dapivirine vaginal ring and daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine were each found to be safe for HIV prevention among cisgender women who started using one of them in their second trimester of pregnancy, according to findings presented today at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver.

5 Mar 2024

Study shows semaglutide as a safe and effective therapy for MASLD in people with HIV

A weekly injection of semaglutide was safe and reduced the amount of fat in the liver by 31% in people with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD), according to a presentation today at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver.

5 Mar 2024